Unión Europea - español - EMA (European Medicines Agency)

astrazeneca ab - selumetinib sulfate - neurofibromatosis 1 - agentes antineoplásicos - koselugo as monotherapy is indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (pn) in paediatric patients with neurofibromatosis type 1 (nf1) aged 3 years and above.

Unión Europea - español - EMA (European Medicines Agency)

roche registration gmbh - polatuzumab vedotin - el linfoma de células b - agentes antineoplásicos - polivy en combinación con bendamustina y rituximab está indicado para el tratamiento de pacientes adultos con recaída/refractaria difuso de células b grandes (dlbcl) que no son candidatos para trasplante de células madre hematopoyéticas. polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (r-chp) is indicated for the treatment of adult patients with previously untreated diffuse large b-cell lymphoma (dlbcl).

Unión Europea - español - EMA (European Medicines Agency)

mylan ire healthcare limited - pretomanid - tuberculosis, resistente a múltiples fármacos - antimicobacterianos - dovprela is indicated in combination with bedaquiline and linezolid, in adults, for the treatment of pulmonary extensively drug resistant (xdr), or treatment-intolerant or nonresponsive multidrug-resistant (mdr) tuberculosis (tb). se debe dar consideración a las directrices oficiales sobre el uso adecuado de agentes antibacterianos.

Unión Europea - español - EMA (European Medicines Agency)

roche registration gmbh - satralizumab - neuromyelitis optica - inmunosupresores - satralizumab (enspryng) is indicated as a monotherapy or in combination with immunosuppressive therapy (ist) for the treatment of neuromyelitis optica spectrum disorders (nmosd) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 igg (aqp4-igg) seropositive.

Unión Europea - español - EMA (European Medicines Agency)

stada arzneimittel ag - budesonide, micronised - glomerulonephritis, iga - antidiarreicos, antiinflamatorio intestinal / contra la infección de los agentes - kinpeygo is indicated for the treatment of primary immunoglobulin a (iga) nephropathy (igan) in adults at risk of rapid disease progression with a urine protein-to-creatinine ratio (upcr) ≥1. 5 g/gram.

Unión Europea - español - EMA (European Medicines Agency)

orchard therapeutics (netherlands) bv - atidarsagene autotemcel - leukodystrophy, metachromatic - otras drogas del sistema nervioso - libmeldy is indicated for the treatment of metachromatic leukodystrophy (mld) characterized by biallelic mutations in the arysulfatase a (arsa) gene leading to a reduction of the arsa enzymatic activity:in children with late infantile or early juvenile forms, without clinical manifestations of the disease,in children with the early juvenile form, with early clinical manifestations of the disease, who still  have the ability to walk independently and before the onset of cognitive decline.

Unión Europea - español - EMA (European Medicines Agency)

swedish orphan biovitrum ab - loncastuximab tesirine - lymphoma, large b-cell, diffuse; lymphoma, b-cell - agentes antineoplásicos - zynlonta as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl), after two or more lines of systemic therapy.

Unión Europea - español - EMA (European Medicines Agency)

pfizer europe ma eeig - glasdegib maleate - leucemia, mieloide, aguda - agentes antineoplásicos - daurismo is indicated, in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (aml) in adult patients who are not candidates for standard induction chemotherapy.

Unión Europea - español - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - belantamab mafodotin - mieloma múltiple - agentes antineoplásicos - blenrep is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

Unión Europea - español - EMA (European Medicines Agency)

insmed netherlands b.v. - amikacin sulfate - infecciones del tracto respiratorio - antibacterianos para uso sistémico, - arikayce liposomal is indicated for the treatment of non-tuberculous mycobacterial (ntm) lung infections caused by mycobacterium avium complex (mac) in adults with limited treatment options who do not have cystic fibrosis.